AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.2700
-0.0090 (-3.23%)
At close: Oct 5, 2026, 4:00 PM EDT
0.2721
+0.0021 (0.78%)
Pre-market: Oct 6, 2026, 8:16 AM EDT
AEON Biopharma Employees
AEON Biopharma had 8 employees as of December 31, 2025. The number of employees increased by 3 or 60.00% compared to the previous year.
Employees
8
Change (1Y)
3
Growth (1Y)
60.00%
Revenue / Employee
n/a
Profits / Employee
-$6,827,875
Market Cap
13.47M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | 3 | 60.00% |
| Dec 31, 2024 | 5 | -5 | -50.00% |
| Jun 30, 2024 | 5 | -4 | -44.44% |
| Dec 31, 2023 | 10 | 2 | 25.00% |
| Jun 30, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 8 | - | - |
| Sep 30, 2022 | 9 | 3 | 50.00% |
| Jun 30, 2021 | 6 | - | - |
| Mar 31, 2021 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 41 |
| Passage Bio | 24 |
| Daré Bioscience | 24 |
| BioLineRx | 24 |
| Citius Pharmaceuticals | 23 |
| Lisata Therapeutics | 21 |
| IN8bio | 18 |
| Tvardi Therapeutics | 12 |
AEON News
- 4 days ago - Aeon Biopharma price target raised to $2 from $1 at Lake Street - TheFly
- 6 days ago - Aeon FDA Type 2b meeting feedback clarifies development plan for ABP-450 - TheFly
- 6 days ago - AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 - GlobeNewsWire
- 27 days ago - Aeon Biopharma announces results from ABP-450 pilot forced degradation study - TheFly
- 27 days ago - AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® - GlobeNewsWire
- 27 days ago - Aeon Biopharma initiated with a Buy at Laidlaw - TheFly
- 5 weeks ago - AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference - GlobeNewsWire
- 6 weeks ago - Aeon Biopharma designates Paul Lee as acting chief regulatory officer - TheFly